Immuron (ASX:IMC), an Australian biopharmaceutical company, has been granted a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease.
This adds to the company's existing patent position in Australia, New Zealand, and the US.
Clostridioides difficile infection (CDI) is a disease of the large intestine caused by toxin-producing bacteria, which can be fatal in severe cases.
The European registration of this patent adds to Immuron's existing patent position, and their product, IMM-529, is intended to prevent and treat C.difficile infections and spare the gut microbiome from the effects of antibiotics.